Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/31
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHurley, James C.*
dc.date.accessioned2012-10-14T22:56:27Zen
dc.date.available2012-10-14T22:56:27Zen
dc.date.issued2008en
dc.identifier.govdoc00018en
dc.identifier.issn0305-7453en
dc.identifier.urihttp://hdl.handle.net/11054/31en
dc.description.abstractBACKGROUND: The ventilator-associated pneumonia incident proportion (VAP-IP) is highly variable among control groups of studies of methods for its prevention. The objective here is to develop and validate a literature-derived benchmark against which these groups can be profiled. METHODS: A literature search yielded 95 cohort groups and control and intervention groups of 150 studies of either non-antimicrobial or antimicrobial methods of VAP prevention. The 95 cohort groups comprise a benchmark set (30 groups), from which the reference funnel plot (RFP) was derived, and a search set (65 groups), against which the benchmark was validated. The VAP-IP data of the benchmark set were found in five published systematic reviews, whereas the VAP-IP data of the search set were abstracted directly from the literature. FINDINGS: Among the 95 cohort groups, the VAP-IP of groups with size >399 was significantly lower than the VAP-IP of smaller groups. Compared with the RFP, 15 of 51 (29%) control groups from studies of antimicrobial methods of VAP prevention with concurrent design were high outlier versus 2 of 110 (2%) control groups from other types of study design (P < 0.001). There were only 22 (14%) outlier groups, all low outlier, among the 162 intervention groups. CONCLUSIONS: Study design factors such as concurrency and study size have potentially greater influence on the VAP-IP than do the VAP prevention methods under study. The outlier status of control groups were inapparent in the individual studies and the meta-analyses and yet would have confounded the estimates of treatment effect.en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2012-10-14T22:56:27Z (GMT) No. of bitstreams: 0en
dc.description.provenanceSubmitted by Gemma Siemensma (gemmas@bhs.org.au) on 2012-10-14T22:56:06ZNo. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2012-10-14T22:56:27Z (GMT). No. of bitstreams: 0 Previous issue date: 2008en
dc.publisherAcademic Pressen
dc.titleProfound effect of study design factors on ventilator-associated pneumonia incidence of prevention studies: benchmarking the literature experience.en
dc.typeJournal Articleen
dc.type.specifiedArticleen
dc.bibliographicCitation.titleThe Journal of Antimicrobial Chemotherapyen
dc.bibliographicCitation.volume61en
dc.bibliographicCitation.issue5en
dc.bibliographicCitation.stpage1154en
dc.bibliographicCitation.endpage1161en
dc.publisher.placeLondonen
dc.subject.healththesaurusRESEARCH SUPPORT - NON U.S GOVERNMENTen
dc.subject.healththesaurusANTI BACTERIAL-AGENTS - THERAPEUTIC USEen
dc.subject.healththesaurusBENCHMARKINGen
dc.subject.healththesaurusCLINICAL TRIALS AS TOPICen
dc.subject.healththesaurusHUMANSen
dc.subject.healththesaurusINCIDENCEen
dc.subject.healththesaurusVENTILATOR ASSOCIATED PNEUMONIAen
dc.subject.healththesaurusRESEARCH DESIGNen
dc.subject.healththesaurusRESPIRATION - ARTIFICIAL - ADVERSE EFFECTSen
dc.date.issuedbrowse2008-01-01en
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.